TUSTIN, Calif., July 18 /PRNewswire-FirstCall/ -- AMDL, Inc. , headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. AMDL announced today that JPI has completed an accelerated, new Corporate Research and Development Process.
Mr. Frank Zheng, Managing Director of JPI, stated that, “JPI’s R&D process focuses on four different strategies that include: in-house product development; licensing global patents from international universities and research centers; licensing China based patents from international research companies; and the collaboration with global drug development companies.”
Mr. Gary Dreher, CEO of AMDL stated, “These efforts will strengthen our pipeline for JPI’s growing family of products, which will ensure our future. JPI’s R&D collaborative process is a well organized asset, which means that we can bring products to market and therefore realize profits sooner. Jade has the potential to build 100 million in annual sales within the next 4 to 5 years.”
The JPI Research and Development Platform now includes a 30 person technical team, a 50 person support staff, which is coupled with 10 various consulting relationships. These R&D consulting relationships are the backbone of JPI’s collaborative product development process. The four key R&D Senior Consultants for JPI are: Prof. Zhao Guo Qing, an expert on plant biology, who is a Professor of Shanghai Second Military Medical University and a visiting professor of Harvard Medical School; Prof. Chen Zhong, an expert on galenic pharmacy, who is a senior consultant at Peking Union Medical College Hospital and a Professor of Jiangxi Medical College; Prof. Zhang Ming Li, President of Pharmacy Research Institute at China Military Medical College; and Prof. Li Shu Zi, Vice President of Ji Lin Traditional Chinese Medicine Research Institute and a Member of Traditional Chinese Medicine Quality Assurance Committee.
JPI’s R&D process takes place at seven locations in China. Two of these are in-house R&D facilities that include the Research Center of YYB, located in Jiangxi, and the Research Center at JJB, located in Jilin. Additionally, five collaborative R&D facilities include: Jilin Traditional Chinese Medicine Research Institute; Baiqiuen Pharmaceutical Research Institute; Research Center of Nanjing Pharmacy University; Jiangxi Bikang Technology Development Co. Ltd.; and the Changsha Continental Pharmaceutical Research Institute.
About Jade:
Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.
Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 Voice Mail: 714.505.4460
AMDL, Inc.
CONTACT: Paul Knopick, +1-949-707-5365, +1-714-505-4460 voice mail, forAMDL Investor Relations
Web site: http://www.amdl.com/
